Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ADA | P00813 | 1/20 | 0.47 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.47 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.47 |
| ▸ | PI4KA | P42356 | 3/20 | 0.46 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.46 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.46 |
| ▸ | AHCY | P23526 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19887008 | 1.00 | POLB (0.47) | POLBADAENPP1P2RY1PI4KA | |
| SCHEMBL25818680 | 0.89 | POLB (0.49) | POLBADAENPP1P2RY1PI4KA | |
| SCHEMBL22060000 | 0.88 | POLB (0.46) | POLBADAENPP1P2RY1PI4KA | |
| SCHEMBL19887007 | 0.85 | POLB (0.48) | POLBADAENPP1P2RY1AHCY | |
| SCHEMBL15280845 | 0.85 | POLB (0.48) | POLBADAENPP1P2RY1AHCY | |
| SCHEMBL24473715 | 0.84 | P2RY1 (0.60) | POLBENPP1P2RY1ADORA1SMN1; SMN2 | |
| SCHEMBL15280904 | 0.84 | POLB (0.51) | POLBENPP1P2RY1ADORA1SMN1; SMN2 | |
| SCHEMBL24784386 | 0.84 | POLB (0.51) | POLBENPP1P2RY1ADORA1SMN1; SMN2 | |
| SCHEMBL15280819 | 0.84 | POLB (0.51) | POLBENPP1P2RY1ADORA1SMN1; SMN2 | |
| SCHEMBL23205584 | 0.83 | POLB (0.47) | POLBENPP1P2RY1STING1ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018516-A1 | Agent for Regulating Expression and/or Function of RPS25 Gene | Sumitomo Pharma Co., Ltd. (JP) | 2024-01-18 | — | — | US | disclosed |
| US-20240018516-A1 | Agent for Regulating Expression and/or Function of RPS25 Gene | Sumitomo Pharma Co., Ltd. (JP) | 2024-01-18 | — | — | US | disclosed |
| US-20220378920-A1 | CONJUGATE OF GalNAc-OLIGONUCLEOTIDE FOR DELIVERY TO LIVER AND MANUFACTURING METHOD THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-12-01 | — | — | US | disclosed |
| US-20210207136-A1 | MYOCARDIAL DYSFUNCTION THERAPEUTIC AGENT | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-07-08 | — | — | US | disclosed |
| US-10731159-B2 | Cationic lipid | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-08-04 | — | — | US | disclosed |
| US-9803199-B2 | Cationic lipid | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-10-31 | — | — | US | disclosed |
| US-9803199-B2 | Cationic lipid | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-10-31 | — | — | US | disclosed |
| US-20160257951-A1 | NOVEL LIPID | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-09-08 | — | — | US | disclosed |
| US-8987226-B2 | Modified single-stranded polynucleotides | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-03-24 | — | — | US | disclosed |
| US-20130253038-A1 | Modified Single-Stranded Polynucleotide | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257951-A1 | NOVEL LIPID | NPC1L1, CETP, LIPC | POLB 394/4885ADA 1502/4885ENPP1 736/4885 |
| US-20240018516-A1 | Agent for Regulating Expression and/or Function of RPS25 Gene | RPS25, RPS26, RPS24 | POLB 685/4885ADA 2344/4885ENPP1 743/4885 |
| US-10731159-B2 | Cationic lipid | CETP, NPC1L1, LIPA | POLB 404/4885ADA 1693/4885ENPP1 1066/4885 |
| US-20220378920-A1 | CONJUGATE OF GalNAc-OLIGONUCLEOTIDE FOR DELIVERY TO LIVER AND MANUFACTURING METHOD THEREOF | CSGALNACT1, GALNT6, GALNT14 | POLB 1098/4885ADA 991/4885ENPP1 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.